Dizziness Three Weeks After Starting a New Heart Failure Drug
A 69-year-old man with HFrEF (EF 28%) is seen three weeks after switching from lisinopril to sacubitril/valsartan 49/51 mg twice daily. He reports less ankle swelling and can now walk two blocks instead of one, but he feels dizzy when standing quickly. BP 96/62 seated and 88/56 standing, HR 74. Potassium 5.3 mEq/L, creatinine 1.5 mg/dL (baseline 1.2), eGFR 44. Weight is down 1.5 kg since the last visit with no orthopnea. He takes a potassium supplement and bought a salt substitute on his wife's advice. He asks whether he should stop the new medication because he 'feels dizzy.'
1. Separate the expected from the harmful in these findings and state which changes require action today.
Read the worked answer
Expected, tolerable effects:
- A modest creatinine rise. An increase up to about 30% from baseline that then plateaus is an anticipated hemodynamic effect of renin-angiotensin system blockade and of decongestion. From 1.2 to 1.5 is 25% - within that band, not automatically a stop signal.
- Lower blood pressure with improved functional capacity. He is walking twice as far with less edema. That is the drug working, not failing.
Findings that require action:
- Potassium 5.3 is the actual problem, and its cause is partly iatrogenic: a potassium supplement plus a potassium-based salt substitute on top of an ARNI and declining renal function. This is additive and correctable.
- Symptomatic orthostatic hypotension (96/62 to 88/56 with symptoms) is a fall risk and is not an acceptable steady state, even though the supine pressure is only modestly low.
- The trajectory is favorable - less edema, more distance, no orthopnea. Do not confuse dizziness from over-diuresis or drug effect with drug failure.
Synthesis: this is a patient benefiting from therapy, with two manageable, largely reversible complications. Stopping the drug would trade a proven mortality benefit for symptom relief that can be obtained another way.
Answer to his question: no, you should not stop it - but we are going to adjust it and remove the things that are stacking on top of it.
2. What is your specific management plan, and what would compel you to stop the drug instead of adjusting it?
Read the worked answer
Today:
- Stop the potassium supplement and the salt substitute. This is the highest-yield, lowest-risk intervention and probably alone fixes the potassium.
- Reduce sacubitril/valsartan to 24/26 mg twice daily rather than discontinuing. Preserve the drug class at a tolerated dose; you can re-titrate once potassium and symptoms settle.
- Audit for other contributors before blaming the ARNI - NSAIDs, trimethoprim-sulfamethoxazole, heparin, additional potassium-sparing diuretics, and any recent contrast.
- Review the diuretic. With a 1.5 kg weight loss, no orthopnea, and reduced edema, his loop diuretic dose may now be excessive. A modest reduction can improve orthostasis without causing congestion.
- Dietary potassium counseling, not just a blanket restriction - give practical, specific guidance.
Recheck in 1 to 2 weeks: basic metabolic panel, seated and standing vital signs, weight, and symptoms.
Stop rather than adjust if:
- Potassium rises above 5.5 or continues climbing despite removing supplements.
- Creatinine rises more than 30% from baseline or continues to climb across two checks rather than plateauing.
- Symptomatic hypotension persists at the reduced dose with inability to maintain perfusion, or he has a fall or syncope.
- Angioedema - an absolute stop, with a 36-hour washout before any ACE inhibitor.
The judgment principle: dose reduction is a tool for preserving a life-prolonging therapy, not a step toward abandoning it. Reserve discontinuation for the specific harms that mandate it.
3. Define how you will evaluate success at the next visit, and what would make you reconsider the whole regimen.
Read the worked answer
Evaluation should be multi-domain, not a single number:
| Domain | What indicates success |
|---|---|
| Symptoms | No orthostatic dizziness; no falls; stable or improved exertional capacity |
| Volume | Weight stable, no edema, no orthopnea or paroxysmal nocturnal dyspnea |
| Hemodynamics | Standing systolic acceptable to him functionally; not necessarily 'normal' |
| Renal | Creatinine plateaued at or near 1.5, not climbing |
| Potassium | Below 5.0 after removing supplements |
| Therapy | On all four guideline-directed classes at the highest tolerated doses, with a documented titration plan |
What success does not look like: a perfect blood pressure. Some degree of low-normal BP is the price of effective HFrEF therapy, and chasing a higher number by backing off every agent produces a comfortable patient with a worse prognosis.
Reconsider the whole regimen if: he develops recurrent congestion while hypotensive (suggesting the problem is the diuretic strategy, not the neurohormonal blockade), potassium remains above 5.5 after removing all exogenous sources, creatinine fails to plateau, or he has syncope. At that point the question becomes which agent to trade off, not whether all of them must be abandoned.
Also evaluate the patient's understanding. He came in ready to stop a beneficial drug because dizziness felt like a signal of harm. Next visit, confirm he can explain why the dose changed and which symptoms should prompt a call - that is the outcome most likely to keep him on therapy.